Evidence map›Paper›PMID 37894431›Full record

ArticleCancers2023

Measurable Residual Disease (MRD) by Flow Cytometry in Adult B-Acute Lymphoblastic Leukaemia (B-ALL) and Acute Myeloid Leukaemia (AML): Correlation with Molecular MRD Testing and Clinical Outcome at One Year.

Riana van der Linde, Prudence N Gatt, Sandy Smith, Marian A Fernandez, Lachlin Vaughan, Emily Blyth, Jennifer Curnow, David A Brown, Elizabeth Tegg, Sarah C Sasson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Riana van der LindeDepartment of Laboratory Haematology, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.ORCID 0000-0003-1152-1920
Prudence N GattFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
Sandy SmithFlow Cytometry Unit, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.
Marian A FernandezFlow Cytometry Unit, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.
Lachlin VaughanDepartment of Laboratory Haematology, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.
Emily BlythFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
Jennifer CurnowFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0000-0002-0569-2873
David A BrownFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.ORCID 0000-0003-1382-9419
Elizabeth TeggDepartment of Laboratory Haematology, Institute of Clinical Pathology and Medical Research, NSW Health Pathology, Westmead Hospital, Westmead, NSW 2145, Australia.
Sarah C SassonFaculty of Medicine and Health, Sydney Medical School, University of Sydney, Camperdown, NSW 2050, Australia.
The University of Sydney · AUWestmead Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Measurable residual disease (MRD) detected by flow cytometry (FC) is well established in paediatric B- lymphoblastic leukaemia (B-ALL) and adult chronic lymphocytic leukaemia (CLL), but its utility in adult B-ALL and adult acute myeloid leukaemia (AML) is less clear. In this prospective MRD study, one of the largest in Australia to date, we examined consecutive bone marrow aspirates from adult participants with B-ALL (

Indexed as

AMLB-ALLmeasurable residual diseaseminimal residual diseasemolecular MRDMRD

Identifiers

PMID37894431
PMCPMC10605425
OpenAlexW4387772756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.